Blueprint cashes in on the past to build its future

Blueprint Medicines has taken an unusual route to raising cash for its R&D pipeline – selling off some of the royalties from its already-approved medicines in return for a cash injectio

Blueprint's latest approval for Ayvakit sets up clash with N...

Blueprint Medicines has claimed its second FDA approval for Ayvakit, getting the nod for advanced systemic mastocytosis (SM), a group of rare blood cancers currently treated mainly by Novar

Blueprint pays the price of Ayvakit phase 3 miss as FDA reje...